DUBLIN–(BUSINESS WIRE)–The “Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest report provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.
Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Idiopathic Pulmonary Fibrosis – Overview
- Idiopathic Pulmonary Fibrosis – Therapeutics Development
- Idiopathic Pulmonary Fibrosis – Therapeutics Assessment
- Idiopathic Pulmonary Fibrosis – Companies Involved in Therapeutics Development
- Idiopathic Pulmonary Fibrosis – Drug Profiles
- Idiopathic Pulmonary Fibrosis – Dormant Projects
- Idiopathic Pulmonary Fibrosis – Discontinued Products
- Idiopathic Pulmonary Fibrosis – Product Development Milestones
- Appendix
Companies Mentioned
- Abeome Corp
- Accendatech Au Pty Ltd
- AdAlta Ltd
- Afimmune Biopharma Ltd
- Algernon Pharmaceuticals Inc
- Altavant Sciences Inc
- Altay Therapeutics Inc
- Amgen Inc
- Amplia Therapeutics Ltd
- AnaMar AB
- Angion Biomedica Corp
- Apaxen
- Aqua Therapeutics Co Ltd
- Aqualung Therapeutics Corp
- Ark Biosciences Inc
- Arroyo BioSciences LLC
- Asahi Kasei Pharma Corp
- AstraZeneca Plc
- Atrapos Therapeutics LLC
- AusBio Ltd
- Avalyn Pharma Inc
- BerGenBio ASA
- Blade Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Bonac Corp
- BreStem Therapeutics Inc
- Bristol-Myers Squibb Co
- Celdara Medical LLC
- CellCure
- Certa Therapeutics Pty Ltd
- Chiesi Farmaceutici SpA
- Chrysalis Pharma SAS
- And Many More Companies!
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2fkbyl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900